Evidence map›Paper›PMID 38637852›Full record

ArticlePediatric blood & cancer2024

IKZF1

Alexandra E Kovach, Maximilian Wengyn, My H Vu, Andrew Doan, Gordana Raca, Deepa Bhojwani

Open access · bronzeAbstract read
In one paragraph

Article in Pediatric blood & cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Interplay between Genetic Ancestry, Self-reported Race and Ethnicity, and Clinical Factors in Pediatric Acute Lymphoblastic Leukemia: A REDIAL Consortium Report.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  3. [Recent advances in individualized treatment for pediatric high-risk B-cell acute lymphoblastic leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Alexandra E KovachHematopathology, Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, California, USA.ORCID 0000-0002-6742-6749
Maximilian WengynMiller School of Medicine of University of Miami, Miami, Florida, USA.
My H VuKeck School of Medicine of University of Southern California, Los Angeles, California, USA.ORCID 0000-0002-2772-7926
Andrew DoanKeck School of Medicine of University of Southern California, Los Angeles, California, USA.ORCID 0000-0002-8362-549X
Gordana RacaKeck School of Medicine of University of Southern California, Los Angeles, California, USA.
Deepa BhojwaniKeck School of Medicine of University of Southern California, Los Angeles, California, USA.
University of Southern California · USUniversity of Miami · US

Funding

USC/CHLA Summer Oncology Research Fellowship (SORF) Program for Medical StudentsR25CA225513 · NCI · CHILDREN'S HOSPITAL OF LOS ANGELES · PI ANAT ERDREICH-EPSTEIN, WIJBE MARTIN KAST · 2019 to 2026
$1.7M
Children's Hospital Los AngelesChildren's Hospital Los Angeles (CH/LA) Department of Pathology and Laboratory Medicine (PLM) Translational Research FundConcern Foundation for Cancer Research, and Tri DeltaInterdisciplinary ResearchNational Cancer Institute R25 CA225513NCI NIH HHS R25 CA225513Norris Comprehensive Cancer Center in Los Angeles
6 · The paper itself

Abstract

backgroundCompared to other ethnicities, Hispanics/Latinos (H/L) have a high incidence of acute lymphoblastic leukemia (ALL), enrichment of unfavorable ALL genetic subtypes, and worse outcomes, even after correcting for socioeconomic factors. We previously demonstrated increased incidence of the high-risk genetic drivers IKZF1 deletion and IGH::CRLF2 rearrangement in H/L compared to non-H/L children with B-ALL. Here in an expanded pediatric cohort, we sought to identify novel genetic drivers and secondary genetic alterations in B-ALL associated with H/L ethnicity. PROCEDURE: Comprehensive clinicopathologic data from patients with B-ALL treated from 2016 to 2020 were analyzed. Subtype was determined from karyotype, fluorescence in situ hybridization (FISH), chromosome microarray (CMA), and our next-generation sequencing (NGS) panel (OncoKids). Non-driver genetic variants were also examined. p-Values less than .05 (Fisher's exact test) were considered significant.

resultsAmong patients with B-ALL at diagnosis (n = 273), H/L patients (189, 69.2%) were older (p = .018), more likely to present with CNS2 or CNS3 disease (p = .004), and NCI high-risk ALL (p = .014) compared to non-H/L patients. Higher incidence of IGH::CRLF2 rearrangement (B-ALL, BCR::ABL1-like, unfavorable; p = .016) and lower incidence of ETV6::RUNX1 rearrangement (favorable, p = .02) were also associated with H/L ethnicity. Among secondary (non-subtype-defining) genetic variants, B-ALL in H/L was associated with IKFZ1 deletion alone (p = .001) or with IGH::CRLF2 rearrangement (p = .003). The IKZF1

conclusionsOur study shows enrichment of high-risk genetic variants in H/L B-ALL and raises consideration for novel therapeutic targets.

Indexed as

Hispanic or LatinoIkaros Transcription FactorPrecursor B-Cell Lymphoblastic Leukemia-LymphomaAdolescentBiomarkers, TumorChildChild, PreschoolFemaleFollow-Up StudiesHumansInfantMalePrognosisSurvival RateBiomarkers, TumorIkaros Transcription FactorIKZF1 protein, humanacute lymphoblastic leukemiaB‐ALLethnicityHispanicleukemiapediatric

Identifiers

PMID38637852
PMCPMC11193948
OpenAlexW4394960234

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.